title: Use of patient-controlled analgesia with alfentanil for burns dressing procedures: a preliminary report of five patients.
abstract: The use of patient-controlled analgesia with alfentanil (PCA-alfentanil) as a form of pain relief for dressing procedures in patients during the acute phase of their burn injuries was investigated. Five ASA 1 and 2 patients with 10-30 per cent total body surface area (TBSA) thermal burns, had PCA-alfentanil for their dressing procedures after standard fluid resuscitation. One patient who did not receive a loading dose and a background infusion of alfentanil had unsatisfactory pain relief. Four patients had good pain relief after a loading dose of IV alfentanil 1 mg followed by a continuous background infusion of 200-800 micrograms/h. Demand dose ranged from 200 to 400 micrograms and lockout time ranged from 1 to 3 min. The total dose of alfentanil delivered ranged from 0.8 to 4.48 mg and duration of the dressings ranged from 30 to 60 min. All patients were mildly sedated, calm, communicative and cooperative during dressing procedures. None of them experienced hypotension or respiratory depression. One patient experienced nausea but no vomiting, no other adverse effects of alfentanil were noted. From the pilot study, PCA-alfentanil may be an effective form of pain relief for dressing procedures in patients during their acute phase of burn injuries. The optimal PCA-alfentanil setting has yet to be determined.
authors.affiliation: Department of Anaesthesia and Surgical Intensive Care, Singapore General Hospital.
authors.forename: K M
authors.initials: KM
authors.lastname: Sim
authors.forename: N C
authors.initials: NC
authors.lastname: Hwang
authors.forename: Y W
authors.initials: YW
authors.lastname: Chan
authors.forename: C S
authors.initials: CS
authors.lastname: Seah
mesh_terms: D000293:Adolescent; D000328:Adult; D015760:Alfentanil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016058:Analgesia, Patient-Controlled; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001458:Bandages / Q000009:adverse effects; D001830:Body Surface Area; D002056:Burns / Q000503:physiopathology / Q000628:therapy*; D003142:Communication; D016292:Procedural Sedation; D003299:Cooperative Behavior; D005260:Female; D005440:Fluid Therapy; D006801:Humans; D007022:Hypotension / Q000517:prevention & control; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000517:prevention & control*; D017060:Patient Satisfaction; D010865:Pilot Projects; D012119:Respiration / Q000187:drug effects
chemical_list: D000701:Analgesics, Opioid; D015760:Alfentanil